GlassScriptPhysician profile
Tat S Lee
NPI 1477500304
$2,820.99
in general payments reported to CMS, 2019-2025
37 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $666 · 2021: $558 · 2022: $142 · 2023: $399 · 2024: $357 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $923.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $375.95 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $357.94 | 2019-2024 | Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $189.24 | 2019-2022 | |
| Lilly USA, LLC | $188.64 | 2019-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $174.26 | 2019-2021 | |
| Gilead Sciences, INC. | $122.30 | 2021-2024 | |
| Boston Scientific Corporation | $106.39 | 2025 | Watchman Flx |
| Merck Sharp & Dohme LLC | $100.76 | 2019-2024 | Gardasil 9, Rotateq, Vaxelis |
| Astellas Pharma US INC | $91.30 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $88.48 | 2019-2024 | |
| Glaxosmithkline, LLC. | $87.23 | 2019-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $79.36 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $76.24 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.64 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $60.85 | 2020-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.46 | 2019-2022 | |
| Pfizer INC. | $54.18 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $53.80 | 2021 | |
| Daiichi Sankyo INC. | $45.95 | 2020-2021 | |
| Abbvie INC. | $45.72 | 2021 | |
| Hologic Sales and Service, LLC | $44.09 | 2024 | Aptima |
| Ironshore Pharmaceuticals INC. | $38.03 | 2024 | |
| Allergan, INC. | $35.87 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $32.55 | 2019-2020 | |
| Axsome Therapeutics, INC. | $30.99 | 2023 | Auvelity |
| Organon LLC | $30.44 | 2023 | Nexplanon, Nuvaring |
| Sanofi-Aventis U.S. LLC | $28.90 | 2021 | |
| Mannkind Corporation | $24.21 | 2020 | |
| Genzyme Corporation | $17.02 | 2019 | |
| Sanofi Pasteur INC. | $16.75 | 2020 | |
| Grifols USA, LLC | $16.67 | 2020 | |
| Alkermes, INC. | $13.75 | 2023 | Vivitrol |
| Kowa Pharmaceuticals America, INC. | $13.49 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.22 | 2021 | |
| Pacira Therapeutics, INC. | $12.38 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.18 | 2020 | |
| Abbott Laboratories | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tat Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.